Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01342380 · ClinicalTrials.gov registry record
Pioglitazone and Quetiapine XR Pharmacogenetic Study
A clinical trial, sponsored by University Hospitals Cleveland Medical Center.
- Completed
- Registry status
- 42
- Enrollment target
NCT01342380 is a clinical trial that has completed, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 42 participants.
The verdict
NCT01342380 has completed, sponsored by University Hospitals Cleveland Medical Center.
- COMPLETED
- Registry status
- 42 participants
- Enrollment target
Study Summary
Obtain phenotypic data and a DNA/blood sample from mood disorder patients undergoing pioglitazone or quetiapine XR treatment as a part of an IRB approved clinical trial conducted at the Mood Disorders Program. Pioglitazone treatment is examined in metabolic syndrome comorbid with bipolar depression (IRB # 07-08-24) and unipolar depression (IRB # 07-07-20). Quetiapine XR treatment is examined in generalized anxiety disorder comorbid with bipolar depression (IRB # 10-06-19) and unipolar depression (IRB # 12-01-29). Please refer to the respective IRB protocols for more information.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2011-02 |
| Est. Completion | 2015-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01342380
The ClinicalTrials.gov registry entry for NCT01342380 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University Hospitals Cleveland Medical Center, which has 230 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01342380 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01342380 about?
NCT01342380 is a clinical study titled "Pioglitazone and Quetiapine XR Pharmacogenetic Study". Obtain phenotypic data and a DNA/blood sample from mood disorder patients undergoing pioglitazone or quetiapine XR treatment as a part of an IRB approved clinical trial conducted at the Mood Disorders Program. Pioglitazone treatment is examined in metabolic syndrome comorbid with bipolar depression ...
What is the current status of trial NCT01342380?
This trial is currently completed. The enrollment target is 42 participants. The study started on 2011-02. Estimated completion is 2015-05.
Who is sponsoring clinical trial NCT01342380?
This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.